Document:

Amendment No. 11

 Exhibit 10.1 
 AMENDMENT NO.11 TO SECOND AMENDED AND RESTATED 
 CREDIT
AGREEMENT 
 THIS AMENDMENT, dated as of November 7, 2012, but effective as of September 30, 2012, by and among
Manitex International, Inc., a Michigan corporation formerly known as Veri-Tek International, Corp., and Manitex, Inc., a Texas corporation (the “Companies”, and individually a “Company”), and Comerica Bank, a Texas banking
association, of Detroit, Michigan (“Bank”). 
 WITNESSETH: 

WHEREAS, Companies and Bank entered into that certain Second Amended and Restated Credit Agreement dated April 11, 2007, as amended
(the “Agreement”); and 
 WHEREAS, Companies and Bank wish to amend the Agreement; 

NOW, THEREFORE, Companies and Bank agree as follows: 
 1. Section 9.3 of the Agreement is amended to read as follows: 

“Guarantee, endorse or otherwise become secondarily liable for or upon the obligations of others, except by endorsement for deposit
in the ordinary course of business, guaranties of the obligations of either Company or any Subsidiary to suppliers, unsecured guaranties of indebtedness owing by CVS Ferrari s.r.l to foreign banks in respect of working capital financing, not to
exceed the lesser of $7.5 million and the amount of such financing, and guaranties in favor of Bank.” 
 2. This Amendment
may be executed in counterparts, of which this is one, all of which shall constitute one and the same instrument. 
 3. Except as
modified hereby, all of the terms and conditions of the Agreement shall remain in full force and effect. Capitalized terms used but not defined herein shall have the meanings given them in the Agreement. 

4. Each Company hereby represents and warrants that, after giving effect to the amendment contained herein, (a) execution, delivery
and performance of this Amendment and any other documents and instruments required under this Amendment or the Agreement are within such Company’s corporate powers, have been duly authorized, are not in contravention of law or the terms of such
Company’s Articles of Incorporation or Bylaws, and do not require the consent or approval of any governmental body, agency, or authority; and this Amendment and any other documents and instruments required under this Amendment or the Agreement,
will be valid and binding in accordance with their terms; (b) the continuing representations and 

 
warranties of such Company set forth in Sections 7.1 through 7.15 of the Agreement are true and correct on and as of the date hereof with the same force and effect as if made on and as of the
date hereof; (c) no Default or Event of Default has occurred and is continuing as of the date hereof. 
 5. This Amendment
shall be effective as of September 30, 2012 upon execution by Companies and Bank. 
 WITNESS the due execution hereof.

  

					
	BANK:	 	 	 	COMPANIES:
			
	COMERICA BANK	 	 	 	MANITEX INTERNATIONAL, INC.
			
	
By: /s/ James Q. Goudie III                
                    
	 		 	By: /s/ David H. Gransee                
	
Its: VP & AGM                   
                  
	 		 	Its: VP &
CFO                                
			
		 		 	MANITEX, INC.
			
		 		 	By: /s/ David H. Gransee                
		 		 	Its: VP &
CFO                                 

  
 22nd Amendment to API Commerical Supply Agreement

 Exhibit 10.1 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
 SECOND AMENDMENT TO API COMMERCIAL
SUPPLY AGREEMENT 
 This SECOND AMENDMENT TO API COMMERCIAL
SUPPLY AGREEMENT (the “Amendment”) is made as of this 19th day of July, 2012 (the “Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the
laws of Ireland and having its principal office at 2 Pembroke House, Upper Pembroke Street, #28-32, Dublin 2, Ireland (“Amarin”), and Chemport Inc., a corporation organized under the laws of South Korea and having its principal offices at
15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (“Chemport”). 
 WHEREAS, the Parties entered into that certain
API Commercial Supply Agreement as of May 25, 2011 (the “Original Agreement”); 
 WHEREAS, the Parties amended
the Original Agreement pursuant to that certain Amendment to API Commercial Supply Agreement dated April 4, 2012 (together with the Original Agreement, the “Agreement”); and 

WHEREAS, the Parties wish to further amend the Agreement as set forth herein. 

NOW THEREFORE, in consideration of the premises and mutual covenants herein below, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1. Capitalized terms used but not
defined herein shall have the meanings given to them in the Agreement. 
 2. Section 4.1 is hereby deleted in its entirety
and replaced with the following: 
 4.1 Capacity. Within [***] months after the Effective Date, Chemport
shall expand the Facility’s capacity to supply annually [***] metric tons of API (with [***]) as further detailed in Schedule 4.1 (the “Expansion”). Following completion of the Expansion, Chemport shall maintain at all times
during the Term the capacity to supply Amarin [***] of API each Calendar Year (“Chemport’s Initial Minimum Capacity”). Chemport’s capacity as further expanded in accordance with this Agreement, together with Chemport’s
Initial Minimum Capacity, shall be referred to herein as “Chemport’s Minimum Capacity.” 
 3. Section 4.2 is
hereby deleted in its entirety and replaced with the following: 
 4.2 Completion. The Expansion will be
deemed to be completed for purposes of this Agreement if (i) all of the requirements set forth in Schedule 4.1 have been satisfied, (ii) Chemport has manufactured three (3) successful, consecutive process validation (consistent
with ICH guidelines) batches (each 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
  

 
batch shall be in a quantity of [***]) of API (each a “Validation Batch”) in the expanded Facility that satisfy the requirements of this Agreement, and (iii) Amarin or mutually
agreed upon Third Party has reviewed the completed process validation report and agrees that it is suitabale to support the approval of the Drug Application. The entire unredacted Process Validation report can be reviewed by aforementioned Third
Party, and Amarin can only review redacted report (redactions will only apply to Chemport confidential process information). Any delays related to review and acceptance of the Process Validation report by Amarin or Third Party shall not constitute a
delay in Chemport’s obligations under this Agreement. 
 4. Schedule 5.1 of the Agreement is deleted in its entirety
and shall be replaced with the Schedule 5.1 attached hereto. 
 5. Section 11.4 of the Agreement is deleted in its entirety
and replaced with the following: 
 11.4 Special Indemnity. In the event this Agreement is terminated by
Amarin pursuant to Sections 15.5(a) or (h), Chemport shall pay to Amarin the amount of [***], which shall be Amarin’s [***], and in the event this Agreement is terminated by Amarin pursuant to Section 15.5(g), Chemport shall pay to Amarin
the amount of [***], which shall [***]. 
 6. The address for Amarin set forth in Section 16.1 of the Agreement is hereby
changed to the following: 
 If to Amarin: 
 Amarin Pharmaceuticals Ireland Ltd. 
 c/o Byrne Wallace; Attention: Thomas Maher

 Upper Pembroke Street, #28-32 
 Dublin 2 
 Ireland 

Telephone +353 1 691 5507 
 Fax + 353 1 691 5010 DX 18 Dublin 
 and 

  
 2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
  

 Amarin Pharmaceuticals Ireland Ltd. 

c/o Amarin Pharma, Inc. 
 1430 Route 206, Suite 200 
 Bedminster, NJ 07921 

USA 

Attention: Senior Vice President, Corporate Development 
 Telephone: 908 719 1315 
 Fax: 908 719 3012 

With a copy (which shall not constitute notice) to: 
 Dan L. O’Korn 
 Hutchison PLLC 

5410 Trinity Road, Suite 400 
 Raleigh, North Carolina 27607 
 Facsimile: (919) 859-1841 

  
 3 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
  

 7. The address for Amarin set forth in Section 16.5 of the Agreement is hereby
changed to the following: 
 Amarin Pharmaceuticals Ireland Ltd. 

c/o Amarin Pharma, Inc. 
 1430 Route 206, Suite 200 
 Bedminster, NJ 07921 

USA 

Attention: Senior Vice President, Corporate Development 
 Telephone: 908 719 1315 
 Fax: 908 719 3012 

8. This Amendment and any other future amendment of the Agreement may be executed in two (2) or more counterparts, each of which
shall be an original, but all of which together shall constitute one and the same instrument. To evidence the fact that it has executed this Amendment and any other future amendment of the Agreement, a Party may send a copy of its executed
counterpart to the other Parties by facsimile transmission or by email transmission in portable document format, or similar format. Signatures of the Parties transmitted by facsimile or by email transmission in portable document format, or similar
format, shall be deemed to be their original signatures for all purposes. 
 9. Except as expressly provided in this Amendment,
all other provisions of the Agreement shall remain unmodified and in full force and effect. 
 [signature page follows]

  
 4 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
  

 [Signature Page to Second Amendment to API Commercial Supply Agreement] 

IN WITNESS WHEREOF, the Parties have caused their duly authorized representative to execute this Amendment effective as of the Amendment
Effective Date. 
  

			
	AMARIN PHARMACEUTICALS IRELAND LTD.
		
	By:	 	 /s/ Conor Dalton

		
	Name:	 	 Conor Dalton

		
	Title:	 	 Chief Administrative Officer

	
	CHEMPORT INC.
		
	By:	 	 /s/ Young Joo Kim

		
	Name:	 	 Young Joo Kim

		
	Title:	 	 CEO/President

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
  

 SCHEDULE 5.1 
 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]